Before the opening bell, International Stem Cell Corp. (OTCQB: ISCO) announced the publication of results from a 12-month preclinical, non-human primate study. The data highlights the safety and efficacy of ISCO’s proprietary human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC®) for the treatment of Parkinson’s disease. According to the results of this study, transplantation of […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.